Showing 2041-2050 of 2314 results for "".
- Moderna Hits 30,000 Enrollment Target in Phase 3 Coronavirus Vaccine Trialhttps://modernod.com/news/moderna-hits-30000-enrollment-target-in-phase-3-coronavirus-vaccine-trial/2478450/Moderna announced that it has completed enrollment of 30,000 participants in the phase 3 COVE study of its investigational coronavirus vaccine mRNA-1273. More than 25,650 participants have so far received their second dose, and Moderna said it will decide whether to seek emergency-use autho
- Appeals Court Skeptical of AHA in Lawsuit Over HHS Price Transparency Rulehttps://modernod.com/news/appeals-court-skeptical-of-aha-in-lawsuit-over-hhs-price-transparency-rule/2478425/A trio of appellate judges was very skeptical of the hospital industry’s arguments that a controversial price transparency rule set to go into effect in January should be struck down, according to a FierceHealthcare
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2020-and-continues-commitment-to-improving-worldwide-access-to-eye-care/2478392/Alcon celebrates World Sight Day through its corporate giving and company-led initiatives focused on improving access to quality eye care. In the spirit of this year’s theme, “Hope in Sight,” Alcon associates will help spark donations to global nonprofit organizations that advance eye health. The
- FDA Releases EUA Guidelines That May Extend Review Time for COVID-19 Vaccineshttps://modernod.com/news/fda-releases-eua-guidelines-that-may-extend-review-time-for-covid-19-vaccines/2478381/The FDA on Tuesday published briefing documents related to an upcoming advisory committee (AdCom) meeting on COVID-19 vaccines, as well as guidance for industry, in which it outlines anticipated stricter criteria that need to be met in order to support an emergency-use authorization (EUA) request
- Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 for Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-treats-first-patients-in-three-phase-3-studies-of-ksi-301-for-retinal-diseases/2478361/Kodiak Sciences announced that the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER, and BEACON studies, three pivotal phase 3 studies of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in treatment-naïve patients with diabetic macular edema (GLEAM
- Zeiss Introduces New Solution Enhancements for Procedure Workflows at ESCRS and Euretinahttps://modernod.com/news/zeiss-introduces-new-solution-enhancements-for-procedure-workflows-at-escrs-and-euretina/2478352/At the ESCRS virtual conference, Zeiss is presenting new solution enhancements aimed at helping doctors maximize clinical efficiency and improve patient care—from assessment, diagnosis, to treatment. Zeiss says the la
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran
- Micro Labs USA Launches Two New Glaucoma Drugshttps://modernod.com/news/new-products-launched-by-micro-labs-usa-inc/2478327/Micro Labs USA is launching two products for the treatment of glaucoma in the United States: Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL. Micro Labs USA said there are additional ophthalmic products under developm
- Trump Signs Executive Orders on Preexisting Condition Protections, Surprise Billinghttps://modernod.com/news/trump-signs-executive-orders-on-preexisting-condition-protections-surprise-billing/2478328/President Donald Trump signed an executive order that declares it a national policy to protect patients with preexisting conditions regardless of the fate of the Affordable Care Act (ACA)—but just how they’ll force insurers to comply remains unclear, according to a FierceHealthcare